Autoimmune Association Leads Sign-On Letter, 64 Patient Groups Ask Congress to Protect Rare Disease Drug Development
December 2021– In a letter sent December 14 to congressional leadership, 64 patient organizations signed on to the Autoimmune Association’s letter asking congress to remove a provision from the currently drafted text of the Build Back Better Act that would dramatically curtail the Orphan Drug Tax Credit for qualified clinical testing expenses by removing a critical incentive for all but the first approved orphan use of a new drug.
Over 90% of rare diseases lack an FDA-approved treatment indicated for the specific rare disease, and since 2016 alone, 23 secondary orphan drug indications have been FDA approved for rare autoimmune diseases. At such a promising time, Congress should be protecting and investing in the future of those without a current FDA approved treatment, rather than removing incentives for the development of future therapies for those who depend on it the most. Click here to read the full letter.
Join our email list
Receive the latest blog articles, news, and more right to your inbox!
Related articles you might be interested in
New Scorecard Highlights Access Barriers Faced by People Living with Autoimmune Diseases
President Biden Signs Legislation that Includes Language to Establish an Office of Autoimmune Disease Research
Autoimmune Association Applauds Key Patient Protections Included in the Inflation Reduction Act; Works to Address Concerns
The Autoimmune Association Supports Recommendations of Report to Advance Research for Autoimmune Diseases
Find more resources on autoimmunity
Learn more about autoimmunity, diagnosis tips, how to find a physician, and more.